New Zealand markets open in 8 hours 5 minutes

Sino Biopharmaceutical Limited (1177.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
2.760+0.120 (+4.55%)
At close: 04:08PM HKT
Currency in HKD

Valuation measures4

Market cap (intra-day) 49.61B
Enterprise value 47.96B
Trailing P/E 24.06
Forward P/E 22.27
PEG ratio (5-yr expected) 1.33
Price/sales (ttm)1.74
Price/book (mrq)1.51
Enterprise value/revenue 1.70
Enterprise value/EBITDA 6.39

Trading information

Stock price history

Beta (5Y monthly) 0.58
52-week change 3-22.81%
S&P500 52-week change 324.96%
52-week high 33.890
52-week low 32.290
50-day moving average 32.800
200-day moving average 33.045

Share statistics

Avg vol (3-month) 356.71M
Avg vol (10-day) 348.83M
Shares outstanding 518.79B
Implied shares outstanding 618.79B
Float 89.28B
% held by insiders 148.21%
% held by institutions 117.40%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.05
Forward annual dividend yield 41.89%
Trailing annual dividend rate 30.05
Trailing annual dividend yield 31.70%
5-year average dividend yield 41.48
Payout ratio 472.63%
Dividend date 3N/A
Ex-dividend date 411 Jun 2024
Last split factor 23:2
Last split date 320 Jul 2020

Financial highlights

Currency in CNY.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 8.90%
Operating margin (ttm)20.76%

Management effectiveness

Return on assets (ttm)5.33%
Return on equity (ttm)12.12%

Income statement

Revenue (ttm)26.2B
Revenue per share (ttm)1.41
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA 6.38B
Net income avi to common (ttm)1.85B
Diluted EPS (ttm)0.110
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)14.12B
Total cash per share (mrq)0.77
Total debt (mrq)12.72B
Total debt/equity (mrq)33.31%
Current ratio (mrq)1.05
Book value per share (mrq)1.66

Cash flow statement

Operating cash flow (ttm)6.07B
Levered free cash flow (ttm)3.01B